| Literature DB >> 19931005 |
Anthony L Keyburn1, Xu-Xia Yan, Trudi L Bannam, Filip Van Immerseel, Julian I Rood, Robert J Moore.
Abstract
A novel toxin, NetB, has recently been identified in virulent avian Clostridium perfringens isolates and shown to be an essential virulence factor in a clinical necrotic enteritis isolate. To assess whether NetB is more generally associated with avian necrotic enteritis isolates we have screened a range of C. perfringens strains from geographically diverse locations for both the presence and expression of the netB gene. Forty-four isolates were derived from necrotic enteritis disease cases from Australia, Belgium, Denmark and Canada and 55 isolates from healthy chickens from Australia and Belgium. The majority of strains isolated from necrotic enteritis-affected birds were netB positive (70%) and there was an absolute correlation between the presence of netB and in vitro expression of the NetB protein. Only two of the C. perfringens isolates from healthy chickens carried netB. Sequencing of the netB gene from 23 positive isolates showed that NetB is highly conserved, with only one predicted amino acid (A168T) difference, in six isolates, compared to the published sequence. This change did not alter the in vitro activity of the NetB toxin. The gene encoding the recently discovered TpeL toxin was also screened using PCR and only found in a small proportion of NetB-positive isolates from diseased birds. A selection of NetB-negative isolates, originating from diseased birds, was unable to cause disease in a necrotic enteritis induction model. This study provides further evidence that NetB is important in pathogenesis and advances our current understanding of C. perfringens virulence factors in avian necrotic enteritis. INRA, EDP Sciences, 2009Entities:
Mesh:
Substances:
Year: 2009 PMID: 19931005 PMCID: PMC2797654 DOI: 10.1051/vetres/2009069
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
Necrotic enteritis C . perfringens strains and PCR, Western blotting and animal trial results.
| Strain | Source | NetB | % disease induction | Reference | ||
|---|---|---|---|---|---|---|
| NAG-NE1 | Aus | − | − | 0 | [ | |
| EHE-NE3 | Aus | + | + | Con | [ | |
| EHE-NE4 | Aus | + | + | Con | [ | |
| EHE-NE5 | Aus | + | + | Con | 47 | [ |
| EHE-NE7 | Aus | + | + | G769A (A168T) | [ | |
| EHE-NE9 | Aus | + | + | G769A (A168T) | [ | |
| EHE-NE13 | Aus | + | + | Con | 87 | [ |
| EHE-NE14 | Aus | + | + | Con | [ | |
| EUR-NE15 | Aus | + | + | Con | 75 | [ |
| EHE-NE16 | Aus | + | + | Con | [ | |
| EHE-NE17 | Aus | + | + | Con | [ | |
| EHE-NE18 | Aus | + | + | Con | 100 | [ |
| EHE-NE20 | Aus | + | + | Con | [ | |
| EHE-NE21 | Aus | + | + | Con | [ | |
| EHE-NE22 | Aus | + | + | Con | [ | |
| NAG-NE23 | Aus | − | − | [ | ||
| NAG-NE24 | Aus | − | − | 0 | [ | |
| NAG-NE25 | Aus | − | − | 11 | [ | |
| UNK-NE30 | Aus | + | NA | 154 | This study | |
| NAG-NE31 | Aus | + | NA | 68 | This study | |
| NAG-NE32 | Aus | + | NA | This study | ||
| BER-NE33 | Aus | − | 0 | This study | ||
| SOM-NE34 | Aus | + | NA | 46 | This study | |
| SOM-NE35 | Aus | + | NA | 77 | This study | |
| GrE ABAT | Can | + | Con | 77 | M. Boulianne, pers. com. | |
| 3 MB 2003 | Can | + | G769A (A168T) | M. Boulianne, pers. com. | ||
| 6 MB 2006 | Can | + | Con | 77 | M. Boulianne, pers. com. | |
| PF3 | Can | − | 0 | M. Boulianne, pers. com. | ||
| SHY07 383 | Can | − | M. Boulianne, pers. com. | |||
| ENV D4 | Can | − | M. Boulianne, pers. com. | |||
| R04-134 | Can | − | M. Boulianne, pers. com. | |||
| R04-104 | Can | − | M. Boulianne, pers. com. | |||
| R03-382 | Can | + | NA | M. Boulianne, pers. com. | ||
| 48 | Bel | − | − | 0 | [ | |
| 67 | Bel | + | + | Con | [ | |
| 56 | Bel | + | + | Con | 80 | [ |
| 37 | Bel | + | + | G769A (A168T) | [ | |
| 200302-1-1-Ba | Den | + | + | Con | L. Bjerrum, pers. com. | |
| 99.63206-34 | Den | + | + | G769A (A168T) | L. Bjerrum, pers. com. | |
| 97.78247-2 | Den | − | − | 0 | L. Bjerrum, pers. com. | |
| 75.65948-1 | Den | + | + | Con | L. Bjerrum, pers. com. | |
| 00.82196-2 | Den | − | − | L. Bjerrum, pers. com. | ||
| 98.78718-2 | Den | + | + | NA | L. Bjerrum, pers. com. | |
| 301001-1-B1 | Den | + | + | G769A (A168T) | L. Bjerrum, pers. com. |
Aus, Australia; Can, Canada; Bel, Belgium; Den, Denmark.
PCR analysis of C. perfringens strains, + indicates netB positive product of 383 bp was amplified, − indicates no amplification product.
Western blot results probing with rNetB anti-serum, + indicates product of 33 kDa, − indicates no product.
C. perfringens netB sequence, NA indicates the netB sequence was not determined, Con indicates EHE-NE18 consensus sequence (EU143239), G769A (A168T) indicates nucleotide change resulting in amino acid change. GenBank accession numbers for netB sequences are FJ189481-FJ189503.
Results of strain use in disease induction model. The results are derived from a series of independent trials. To allow a simple comparison of all the results, the average lesion score for each group was compared to the lesion score for EHE-NE18 challenge in the same trial (included in all trials as our standard challenge strain).
Indicates C. perfringens strains that are tpeL positive with a product size of 474 bp.
Indicates C. perfringens isolate from diseased turkey.
Figure 1.Western blot of NetB toxin from C. perfringens isolates from diseased chickens. Proteins were separated by 4–12% SDS-PAGE. SeeBlue Plus2 prestained marker (Invitrogen) was used as a size marker. Bands were transferred onto PVDF membranes and probed with rabbit polyclonal anti-rNetB antibody. Blots were developed with an ECL Western blotting kit and the results recorded on autoradiographic film. Strains: (1) EHE-NE18; (2) NAG-NE1; (3) 48; (4) 56; (5) 301001-1-B1.
Figure 2.Cytotoxic activity of NetB (A168T) supernatants on LMH cells. The LMH cells were grown to 70% confluence in a 96 well tissue culture plate and culture supernatant added to the medium for 4 h at 37 °C. Cytotoxicity was measured by release of LDH from the the LMH cells using the CytoTox kit (Promega). (A) EHE-NE18; (B) EHE-NE7; (C) EHE-NE9; (D) 3 MB-2003; (E) 37; (F) 301001-1-B1. (1) Dialyzed culture supernatant; (2) culture supernatant pre-incubated with pre-immune serum for 1 h at 37 °C; (3) culture supernatant pre-incubated with rNetB anti-serum for 1 h at 37 °C. The values are averages of triplicate assays with error bars representing SD.